+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted SSTR Radionuclide Drug Conjugates Market by Radiometal Type, Peptide Analog, Treatment Indication, Clinical Phase, End User, Distribution Channel - Global Forecast to 2030- Product Image
Targeted SSTR Radionuclide Drug Conjugates Market by Radiometal Type, Peptide Analog, Treatment Indication, Clinical Phase, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Targeted SSTR Radionuclide Drug Conjugates Market by Radiometal Type, Peptide Analog, Treatment Indication, Clinical Phase, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082278
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

A New Era in SSTR-Targeted Radionuclide Therapies

In recent years, the convergence of molecular imaging and targeted therapy has ushered in a transformative chapter for precision oncology. Somatostatin receptor-targeted radionuclide drug conjugates harness the affinity of peptide analogs for overexpressed receptors on malignant cells, delivering therapeutic radionuclides with remarkable specificity. This approach mitigates off-target toxicity while amplifying antitumor efficacy, marking a departure from conventional cytotoxic treatments.

As regulatory agencies worldwide embrace theranostic paradigms, a wave of novel conjugates is advancing through clinical pipelines. Collaboration among nuclear medicine specialists, radiochemists, and oncologists has unlocked scalable production methods for complex radiometals and streamlined quality-control frameworks. The intersection of innovative peptide design and state-of-the-art radionuclide labeling technology underscores an evolving landscape where drug conjugates are no longer niche interventions but foundational components of personalized treatment regimens.

This executive summary synthesizes critical insights into the market’s evolving contours, laying the groundwork for informed decision-making. By examining the catalysts that are accelerating therapeutic adoption, identifying emerging competitive threats, and mapping regional growth patterns, we provide an authoritative guide to stakeholders poised to capitalize on this high-growth segment.

Driving Forces Redefining Radioconjugate Drug Development

Theranostic integration, digital manufacturing platforms, and collaborative regulatory frameworks are steering a profound realignment within targeted radioconjugate development. The transition from purely beta-emitting isotopes to alpha-particle therapies has unlocked new therapeutic windows, enabling eradication of micrometastatic lesions with subcellular precision. Concurrently, advances in high-throughput peptide synthesis and automated radiolabeling systems have compressed production timelines, empowering decentralized radiopharmacies to deliver patient-specific doses on demand.

On the regulatory front, harmonization efforts between major agencies are reducing approval lag times, while adaptive trial designs foster seamless learning between early-stage safety assessments and pivotal efficacy studies. Strategic alliances between pharmaceutical developers and academic research institutions are accelerating the translation of first-in-class conjugates from bench to bedside, supported by open-access databases for dosimetry and imaging biomarkers. These shifts collectively redefine the competitive arena, elevating collaboration and platform scalability as critical success factors in a landscape where agility and innovation converge.

Navigating the Impact of US Tariffs on Radiotherapeutics

The introduction of new import tariffs on radionuclide precursors and advanced medical isotopes in 2025 has reverberated across supply chains, compelling manufacturers to reassess sourcing strategies. Tariff adjustments on key radiometal raw materials have inflated production costs for Lutetium 177, Tritium-90 and emerging alpha emitters, creating headwinds for companies reliant on overseas supply. In response, several developers are accelerating investments in domestic cyclotron infrastructure and forging partnerships with regional isotope producers to mitigate exposure to trade policy volatility.

Although increased onshore capacity promises resilience, build-out timelines and capital intensity raise near-term supply constraints. To preserve margin profiles, organizations are optimizing their regulatory filings to expedite approvals for alternative isotopic production routes. At the same time, health systems are reevaluating procurement frameworks, leveraging creative contracting mechanisms to buffer financial impact. Overall, the 2025 tariff regime has catalyzed a strategic pivot toward supply chain diversification, while catalyzing dialogues with policymakers on establishing harmonized tariff carve-outs for life-saving radionuclides.

Deep Dive into Segmentation Reveals Growth Pathways

An in-depth view of radiometal performance shows Actinium 225 delivering potent alpha emissions for refractory tumor profiles while Lutetium 177 maintains a dominant position in neuroendocrine oncology due to its well-characterized safety profile, and Yttrium 90 retains traction in combination therapies. When examining peptide analog variations, Dotanoc is gaining interest for its multi-receptor binding properties, Dotatate demonstrates robust clinical adoption through established efficacy in key indications, and Dotatoc continues to thrive where pharmacokinetic flexibility is prized. Treatment indication analysis highlights the expanding role of radionuclide conjugates in neuroendocrine tumor management, alongside emerging investigational use in thyroid malignancies. Clinical phase segmentation reveals a maturing commercial portfolio complemented by a vigorous early-stage pipeline spanning preclinical discovery through Phase III validation. Insights into end-user engagement indicate that hospital settings dominate therapeutic administration, while research institutes advance translational studies and specialty clinics pioneer outpatient dosing models. Evaluating distribution dynamics shows that direct procurement by large academic centers coexists with distributor networks and competitive tender programs, each shaping access and pricing landscapes in distinct ways.

Regional Dynamics Shaping Global Radioconjugate Adoption

Market dynamics in the Americas underscore strong reimbursement mechanisms and leading-edge clinical trial activity, with patient advocacy groups driving accelerated adoption in major cancer centers. Regulatory agencies in Europe, Middle East & Africa exhibit growing alignment on radiopharmaceutical guidelines, supporting cross-border clinical collaborations, while emerging markets in the region are investing in local radiochemistry capabilities to reduce import dependencies. Within Asia-Pacific, government funding initiatives and public-private partnerships are enhancing cyclotron capacity, and national health insurance reforms are expanding patient access to advanced therapies. Cross-regional partnerships are emerging as essential conduits for technology transfer and best-practice exchange, enabling a more integrated global supply ecosystem and fostering equitable access to next-generation SSTR-targeted treatments.

Strategic Profiles of Leading Industry Innovators

Leading developers continue to set the pace, with a diversified portfolio of late-stage conjugates positioning them for rapid market entry. Strategic acquisitions have bolstered capabilities in radiometal production, while cross-sector alliances are unlocking novel peptide scaffolds that enhance binding affinity and therapeutic index. Mid-sized innovators are leveraging nimble R&D infrastructures to pursue niche indications, harnessing real-world data to refine dosimetry algorithms and patient selection criteria. Collaborative consortia are pooling resources to establish standardized manufacturing protocols and shared tracer libraries, reducing redundancy and expediting regulatory pathways. At the same time, several organizations are deploying machine-learning platforms for predictive stability testing, augmenting traditional quality assurance processes. These varied strategic initiatives underscore a competitive landscape where scientific rigor, operational excellence, and partnership agility are key differentiators.

Practical Steps for Leadership in Radionuclide Therapy

To maintain competitive advantage, organizations should prioritize investment in scalable radioisotope production, exploring modular cyclotron designs that can be rapidly deployed at regional centers. Cultivating partnerships with academic and government laboratories will accelerate access to novel peptide analogs and streamline regulatory submissions through shared data repositories. Companies must also advocate for targeted tariff relief measures, engaging with trade authorities to underscore the public health imperatives of uninterrupted radionuclide supply. Implementing digital traceability systems across the distribution chain will enhance patient safety and operational transparency, while embedding artificial intelligence in dosimetry planning can optimize therapeutic windows. Finally, aligning commercial strategies with patient advocacy groups will foster broader acceptance and facilitate reimbursement discussions, ensuring that advanced therapies reach those in need.

Rigorous Framework Underpinning Our Market Study

Our analysis integrates primary interviews with nuclear medicine experts, regulatory officials, and supply chain executives to capture nuanced perspectives on market drivers and barriers. Secondary research encompasses peer-reviewed journals, patent filings, clinical trial registries, and agency guidelines to ensure comprehensive coverage of technological, clinical, and policy trends. Data triangulation methods validate conflicting viewpoints, while proprietary scoring models assess the relative maturity of radionuclide platforms across multiple dimensions. Regional insights draw upon localized stakeholder workshops and field surveys, offering granularity on reimbursement frameworks and infrastructure readiness. Rigorous quality controls, including dual-review processes and continual updates, guarantee that the findings remain current and relevant for strategic planning.

Synthesizing Insights and Charting the Path Forward

The evolution of SSTR-targeted radionuclide conjugates reflects a confluence of scientific breakthroughs, regulatory innovation, and market strategy refinement. Early adopters have demonstrated the feasibility of delivering high-precision therapies with manageable safety profiles, laying the groundwork for broader therapeutic applications. Yet, supply chain vulnerabilities and tariff headwinds underscore the need for proactive risk mitigation. Regional analysis reveals diverse growth trajectories, shaped by reimbursement policies, infrastructure investments, and collaborative networks.

Looking ahead, the alignment of clinical data generation with real-world evidence platforms will be pivotal in securing long-term payer support. Enhanced manufacturing scalability, coupled with strategic alliances, will determine which organizations emerge as leaders in the next phase of market expansion. By synthesizing the insights presented here, stakeholders can navigate the complexity of this rapidly evolving landscape and position themselves to deliver transformative treatments to patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Radiometal Type
    • Actinium 225
    • Lutetium 177
    • Yttrium 90
  • Peptide Analog
    • Dotanoc
    • Dotatate
    • Dotatoc
  • Treatment Indication
    • Neuroendocrine Tumors
    • Thyroid Cancer
  • Clinical Phase
    • Commercial
    • Phase I
    • Phase II
    • Phase III
    • Preclinical
  • End User
    • Hospital
    • Research Institutes
    • Specialty Clinics
  • Distribution Channel
    • Direct Procurement
    • Distributor Sales
    • Tender
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Lantheus Holdings, Inc.
  • Ipsen SA
  • Curium Pharma
  • Jubilant Radiopharma Limited
  • ITM Isotope Technologies Munich SE
  • RayzeBio, Inc.
  • Telix Pharmaceuticals Limited
  • Cardinal Health, Inc.
  • Eckert & Ziegler Radiopharma GmbH

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted SSTR Radionuclide Drug Conjugates Market, by Radiometal Type
8.1. Introduction
8.2. Actinium 225
8.3. Lutetium 177
8.4. Yttrium 90
9. Targeted SSTR Radionuclide Drug Conjugates Market, by Peptide Analog
9.1. Introduction
9.2. Dotanoc
9.3. Dotatate
9.4. Dotatoc
10. Targeted SSTR Radionuclide Drug Conjugates Market, by Treatment Indication
10.1. Introduction
10.2. Neuroendocrine Tumors
10.3. Thyroid Cancer
11. Targeted SSTR Radionuclide Drug Conjugates Market, by Clinical Phase
11.1. Introduction
11.2. Commercial
11.3. Phase I
11.4. Phase II
11.5. Phase III
11.6. Preclinical
12. Targeted SSTR Radionuclide Drug Conjugates Market, by End User
12.1. Introduction
12.2. Hospital
12.3. Research Institutes
12.4. Specialty Clinics
13. Targeted SSTR Radionuclide Drug Conjugates Market, by Distribution Channel
13.1. Introduction
13.2. Direct Procurement
13.3. Distributor Sales
13.4. Tender
14. Americas Targeted SSTR Radionuclide Drug Conjugates Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Lantheus Holdings, Inc.
17.3.3. Ipsen SA
17.3.4. Curium Pharma
17.3.5. Jubilant Radiopharma Limited
17.3.6. ITM Isotope Technologies Munich SE
17.3.7. RayzeBio, Inc.
17.3.8. Telix Pharmaceuticals Limited
17.3.9. Cardinal Health, Inc.
17.3.10. Eckert & Ziegler Radiopharma GmbH
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET MULTI-CURRENCY
FIGURE 2. TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM 225, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM 177, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY YTTRIUM 90, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTANOC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATOC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PROCUREMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. CANADA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 47. CANADA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 49. CANADA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. CANADA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. MEXICO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 52. MEXICO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 53. MEXICO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. UNITED KINGDOM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED KINGDOM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. GERMANY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 83. GERMANY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 84. GERMANY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 85. GERMANY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 86. GERMANY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. GERMANY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. FRANCE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 89. FRANCE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 90. FRANCE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 91. FRANCE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 92. FRANCE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. FRANCE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. RUSSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 95. RUSSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ITALY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 101. ITALY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 102. ITALY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 103. ITALY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 104. ITALY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. ITALY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SPAIN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 107. SPAIN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 108. SPAIN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 109. SPAIN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 110. SPAIN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. SPAIN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. UNITED ARAB EMIRATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED ARAB EMIRATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. DENMARK TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 132. DENMARK TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. DENMARK TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. QATAR TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 143. QATAR TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 144. QATAR TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 145. QATAR TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 146. QATAR TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. QATAR TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. FINLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 149. FINLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 150. FINLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 151. FINLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 152. FINLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. FINLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SWEDEN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 155. SWEDEN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. NIGERIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. EGYPT TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 168. EGYPT TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 169. EGYPT TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 170. EGYPT TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. EGYPT TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. TURKEY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 173. TURKEY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 174. TURKEY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 175. TURKEY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 176. TURKEY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. TURKEY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NORWAY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 185. NORWAY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 186. NORWAY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 187. NORWAY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 188. NORWAY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. NORWAY TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. POLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 191. POLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 192. POLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 193. POLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 194. POLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. POLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SWITZERLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 209. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 210. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 211. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 212. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 213. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. INDIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 216. INDIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 217. INDIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 218. INDIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 219. INDIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. INDIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. JAPAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 222. JAPAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 223. JAPAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 224. JAPAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 225. JAPAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. JAPAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. THAILAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 246. THAILAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 247. THAILAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 248. THAILAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 249. THAILAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. THAILAND TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2

Companies Mentioned

The companies profiled in this Targeted SSTR Radionuclide Drug Conjugates market report include:
  • Novartis AG
  • Lantheus Holdings, Inc.
  • Ipsen SA
  • Curium Pharma
  • Jubilant Radiopharma Limited
  • ITM Isotope Technologies Munich SE
  • RayzeBio, Inc.
  • Telix Pharmaceuticals Limited
  • Cardinal Health, Inc.
  • Eckert & Ziegler Radiopharma GmbH

Methodology

Loading
LOADING...

Related Reports

Pheochromocytomas and Paragangliomas (PCPG)- Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Pheochromocytomas and Paragangliomas (PCPG)- Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 172 Pages
  • Global
From
Neuroendocrine Tumors - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Neuroendocrine Tumors - Market Insight, Epidemiology and Market Forecast - 2034

  • Drug Pipelines
  • 247 Pages
  • Global
From
Targeted PSMA Radionuclide Drug Conjugates Market by Radionuclide Type, Indication, Therapy Type, End User, Distribution Channel, Administration Route, Patient Age Group - Global Forecast to 2030 - Product Image

Targeted PSMA Radionuclide Drug Conjugates Market by Radionuclide Type, Indication, Therapy Type, End User, Distribution Channel, Administration Route, Patient Age Group - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Next Generation Drug Conjugates Market Report 2025 - Product Image

Next Generation Drug Conjugates Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Next Generation Drug Conjugates Market 2024 - Product Image

Next Generation Drug Conjugates Market 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.